blood cell cancer hematological malignancies
Conditions
Interventions
Eligible patients will receive one cycle of donor DC vaccination consisting of
maximal 3 immunizations, given at 2 week intervals. MiHA mRNA-electroporated
donor DC will be infused intravenously (2.
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Patients with AML, myelodysplasia (MDS), ALL, CML (accelerated or blast phase), CLL, MM or malignant NHL, who underwent HLA-matched allo-SCT * Patients positive for HLA-A2 and/or HLA-B7 * Patients positive for HA-1, LRH-1 and/or ARHGDIB transplanted with corresponding MiHA-negative donor * Patients >18 and
Exclusion criteria
Exclusion criteria: * Life expectancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study parameters are to evaluate the safety, toxicity, development of GVHD and the immunological response by appearance of MiHA-specific CD8+ T cells following vaccination with monocyte-derived donor DC electroporated with mRNA encoding hematopoietic-restricted MiHA in patients who had undergone allo-SCT with stem cells from HLA-matched, MiHA-mismatched donor. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study parameters are to evaluate the clinical effect of MiHA-DC vaccination in case of detectable minimal residual disease and mixed chimerism. | — |
Countries
Netherlands
Outcome results
None listed